Background: Tumour necrosis factor (TNF) plays a pivotal role in controlling intracellular of bacterial infection. The BSR Biologics Register (BSRBR) has reported an increase in the occurrence of listeria and salmonella infections in anti-TNF-treated rheumatoid arthritis patients in comparison with those patients treated with non-biological DMARDs. Objectives: The aim of this study was to determine the incidence of gastrointestinal infection in the anti-TNF-treated spondyloarthritis (SpA) patients in the GISEA registry, and identify the factors associated with its development. Methods: The prospective GISEA registry was designed to collect real-world clinical data concerning patients with RA or SpA treated with biological drugs. The baseline information includes demographics, disease duration, HAQ-DI, DAS-28, BASDAI, BASFI and BASMI scores, steroid use, smoking history and comorbidities. Results: Of the 3321 anti-TNF-treated SpA patients in the registry (1731 males, 52.2%; mean age 47±13 years; median disease duration three years, interquartile range [IQR] 0–8), 1065 (32%) were treated with infliximab (IFN), 1052 (32%) with adalimumab (ADA), and 1204 (36%) with etanercept (ETN). Two thousand, one hundred and five patients (63.4%) had a median of one comorbidity (IQR 0–2], the most frequent being hypertension (701), thyroid diseases (281), diabetes mellitus (207), cardiopathy (189), and osteoporosis (145). In combination with the biological drug, 919 patients (27.7%) received steroids and 2451 (79.9%) at least one DMARD. The median follow-up was three months (IQR 1–2 years). Twenty-two patients 0.7% experienced bacterial gastrointestinal infections, the most frequent being due to listeria, klebsilla and salmonella. The crude incidence rate was 2.5 per 1000 patient-years (95% CI 1.6–3.7). Univariate analysis showed that female gender (OR 3.9, 95% CI 1.5–10.0; p=0.004) and comorbidities (OR 3.4, 95% CI 1.0–3.5; p=0.049) were associated with a high risk of gastrointestinal infections, and that the use of IFN rather than ETN and ADA (p=0.712 and p=0.238) was not associated with a higher risk of gastrointestinal infections. Furthermore, univariate models showed that age (p=0.738), disease duration p=0.090, previous DMARDs (p=0.616), and HAQ (p=0.674) and BASFI (scores p=0.850) were not statistically significant predictors of gastrointestinal infections. Conclusions: The incidence rate of gastrointestinal infections in SpA patients treated with anti-TNF drugs is not increased. Being female and having comorbidities are predictive factors of gastrointestinal infections.

THU0366 Gastrointestinal infections in patients with spondyloarthritis treated with anti-tnf drugs: results of gisea register / Atzeni, F.; Panetta, V.; Sebastiani, M.; Salaffi, F.; Carletto, A.; Foti, R.; Iannone, F.; Elisa, G.; Govoni, M.; Marchesoni, A.; Favalli, E. G.; Gorla, R.; Ramonda, R.; Sarzi-Puttini, P.; Ferraccioli, G.; Lapadula, G.. - In: ANNALS OF THE RHEUMATIC DISEASES. THE EULAR JOURNAL. - ISSN 1792-328X. - 76:(2017), pp. 343-344. ((Intervento presentato al convegno EULAR Congress of Rheumatology tenutosi a Madrid [10.1136/annrheumdis-2017-eular.5936].

THU0366 Gastrointestinal infections in patients with spondyloarthritis treated with anti-tnf drugs: results of gisea register

M. sebastiani;
2017

Abstract

Background: Tumour necrosis factor (TNF) plays a pivotal role in controlling intracellular of bacterial infection. The BSR Biologics Register (BSRBR) has reported an increase in the occurrence of listeria and salmonella infections in anti-TNF-treated rheumatoid arthritis patients in comparison with those patients treated with non-biological DMARDs. Objectives: The aim of this study was to determine the incidence of gastrointestinal infection in the anti-TNF-treated spondyloarthritis (SpA) patients in the GISEA registry, and identify the factors associated with its development. Methods: The prospective GISEA registry was designed to collect real-world clinical data concerning patients with RA or SpA treated with biological drugs. The baseline information includes demographics, disease duration, HAQ-DI, DAS-28, BASDAI, BASFI and BASMI scores, steroid use, smoking history and comorbidities. Results: Of the 3321 anti-TNF-treated SpA patients in the registry (1731 males, 52.2%; mean age 47±13 years; median disease duration three years, interquartile range [IQR] 0–8), 1065 (32%) were treated with infliximab (IFN), 1052 (32%) with adalimumab (ADA), and 1204 (36%) with etanercept (ETN). Two thousand, one hundred and five patients (63.4%) had a median of one comorbidity (IQR 0–2], the most frequent being hypertension (701), thyroid diseases (281), diabetes mellitus (207), cardiopathy (189), and osteoporosis (145). In combination with the biological drug, 919 patients (27.7%) received steroids and 2451 (79.9%) at least one DMARD. The median follow-up was three months (IQR 1–2 years). Twenty-two patients 0.7% experienced bacterial gastrointestinal infections, the most frequent being due to listeria, klebsilla and salmonella. The crude incidence rate was 2.5 per 1000 patient-years (95% CI 1.6–3.7). Univariate analysis showed that female gender (OR 3.9, 95% CI 1.5–10.0; p=0.004) and comorbidities (OR 3.4, 95% CI 1.0–3.5; p=0.049) were associated with a high risk of gastrointestinal infections, and that the use of IFN rather than ETN and ADA (p=0.712 and p=0.238) was not associated with a higher risk of gastrointestinal infections. Furthermore, univariate models showed that age (p=0.738), disease duration p=0.090, previous DMARDs (p=0.616), and HAQ (p=0.674) and BASFI (scores p=0.850) were not statistically significant predictors of gastrointestinal infections. Conclusions: The incidence rate of gastrointestinal infections in SpA patients treated with anti-TNF drugs is not increased. Being female and having comorbidities are predictive factors of gastrointestinal infections.
76
343
344
Atzeni, F.; Panetta, V.; Sebastiani, M.; Salaffi, F.; Carletto, A.; Foti, R.; Iannone, F.; Elisa, G.; Govoni, M.; Marchesoni, A.; Favalli, E. G.; Gorla, R.; Ramonda, R.; Sarzi-Puttini, P.; Ferraccioli, G.; Lapadula, G.
THU0366 Gastrointestinal infections in patients with spondyloarthritis treated with anti-tnf drugs: results of gisea register / Atzeni, F.; Panetta, V.; Sebastiani, M.; Salaffi, F.; Carletto, A.; Foti, R.; Iannone, F.; Elisa, G.; Govoni, M.; Marchesoni, A.; Favalli, E. G.; Gorla, R.; Ramonda, R.; Sarzi-Puttini, P.; Ferraccioli, G.; Lapadula, G.. - In: ANNALS OF THE RHEUMATIC DISEASES. THE EULAR JOURNAL. - ISSN 1792-328X. - 76:(2017), pp. 343-344. ((Intervento presentato al convegno EULAR Congress of Rheumatology tenutosi a Madrid [10.1136/annrheumdis-2017-eular.5936].
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1167064
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact